Don't combine sartans and ACE-inhibitors, says EU's CHMP
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's main scientific committee, the CHMP, has advised against combining different classes of drugs that act on the renin-angiotensin system (RAS) in patients with cardiovascular problems, on the grounds that dual therapy does not increase the benefits of treatment and can increase the risk of serious cardiovascular and renal side-effects.